(Q37409352)

20 August 2017

3 references

19 June 2019

29 May 2020

26 January 2021

Economic aspects of bladder cancer: what are the benefits and costs? (English)

1 reference

20 August 2017

2 references

19 June 2019

26 January 2021

2 references

26 January 2021

1 reference

K D Sievert

1 reference

20 August 2017

B Amend

1 reference

20 August 2017

U Nagele

1 reference

20 August 2017

D Schilling

1 reference

20 August 2017

J Bedke

1 reference

20 August 2017

M Horstmann

1 reference

20 August 2017

J Hennenlotter

1 reference

20 August 2017

S Kruck

1 reference

20 August 2017

A Stenzl

1 reference

20 August 2017

7 March 2009

1 reference

20 August 2017

1 June 2009

5 references

3 April 2019

22 April 2019

19 June 2019

29 May 2020

26 January 2021

World Journal of Urology

6 references

20 August 2017

3 April 2019

22 April 2019

19 June 2019

29 May 2020

26 January 2021

1 reference

20 August 2017

1 reference

20 August 2017

295-300

1 reference

Creative Commons Attribution-NonCommercial 2.0 Generic

20 August 2017

start time

7 March 2009

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Patient time costs associated with cancer care

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

The health economics of bladder cancer: a comprehensive review of the published literature.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Fluorescence detection of bladder cancer: a review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Estimating health care costs related to cancer treatment from SEER-Medicare data

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Office evaluation and management of bladder neoplasms

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Clinical model of lifetime cost of treating bladder cancer and associated complications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

The economic consequences of prostate and bladder cancer in the UK.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Clinical model of cost of bladder cancer in the elderly

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Bladder and upper tract urothelial cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Influence of post-cystectomy complications on cost and subsequent outcome

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Out-of-pocket health-care expenditures among older Americans with cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694315

The use of molecular diagnostics in bladder cancer

2 September 2018

1 reference

12 December 2020

Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis

1 reference

12 December 2020

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up

1 reference

12 December 2020

Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study

1 reference

12 December 2020

Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results

1 reference

12 December 2020

Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis

1 reference

12 December 2020

Economics of notification and medical screening for high-risk workers

1 reference

12 December 2020

Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma

1 reference

12 December 2020

Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome

1 reference

12 December 2020

10.1007/S00345-009-0395-Z

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19271220

1 reference